Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

273
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
273
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
Inhaled Medications01:23

Inhaled Medications

288
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
288
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

458
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
458
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

COPD maintenance trials use heterogeneous outcomes and measurement instruments: a systematic literature review.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

ERS Congress 2025: highlights from the Airway Diseases Assembly.

ERJ open research·2026
Same author

Find your career: the ERS "My Career Path" series.

Breathe (Sheffield, England)·2026
Same author

Blood eosinophil count as a biomarker for therapy guidance in COPD and asthma exacerbations.

Breathe (Sheffield, England)·2026
Same author

Energy and Protein Intake in Mild-Moderate COPD Patients.

Lung·2026
Same author

Activation of STAT3 in the COPD airway epithelium.

ERJ open research·2026

Related Experiment Video

Updated: Jul 13, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K

How inhaled corticosteroids target inflammation in COPD.

Simon Lea1, Andrew Higham2, Augusta Beech2

  • 1Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK Simon.lea@manchester.ac.uk.

European Respiratory Review : an Official Journal of the European Respiratory Society
|October 18, 2023
PubMed
Summary

Inhaled corticosteroids (ICS) benefit selected patients with chronic obstructive pulmonary disease (COPD) who have a higher risk of exacerbations and elevated blood eosinophil counts (BEC). Response varies due to complex interactions between lung microbiome and airway inflammation.

More Related Videos

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.7K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.0K

Related Experiment Videos

Last Updated: Jul 13, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.7K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.7K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.0K

Area of Science:

  • Pulmonology
  • Immunology
  • Microbiology

Background:

  • Chronic obstructive pulmonary disease (COPD) is often considered corticosteroid-resistant.
  • Inhaled corticosteroids (ICS) are primary anti-inflammatory treatments for COPD.
  • Patient response to ICS varies significantly.

Purpose of the Study:

  • To review ICS-modulated inflammation in COPD.
  • To explore reasons for variable ICS response.
  • To discuss the role of the lung microbiome and blood eosinophil count (BEC) in ICS efficacy.

Main Methods:

  • Literature review of clinical trials and mechanistic studies.
  • Analysis of inflammatory pathways affected by ICS.
  • Examination of the impact of ICS on the lung microbiome.
  • Discussion of BEC as a biomarker for ICS selection.

Main Results:

  • ICS can reduce type 2 inflammation and mast cell numbers.
  • Some COPD inflammatory pathways (e.g., bacteria-induced IL-8) are corticosteroid-insensitive.
  • ICS can alter the lung microbiome, decreasing diversity and increasing Proteobacteria.
  • Blood eosinophil count (BEC) helps select COPD patients who benefit from ICS.

Conclusions:

  • ICS efficacy in COPD is selective, particularly for patients with high exacerbation risk and BEC.
  • Individual response is influenced by a complex interplay of airway inflammation and lung microbiome.
  • Understanding these interactions is key to optimizing ICS therapy in COPD.